Current status of small molecule drug development for Ebola virus and other filoviruses.

Authors:
Megan R Edwards
Megan R Edwards
Washington University School of Medicine
United States
Christopher F Basler
Christopher F Basler
Icahn School of Medicine at Mount Sinai
New York | United States

Curr Opin Virol 2019 Apr 16;35:42-56. Epub 2019 Apr 16.

Center for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, United States. Electronic address:

The filovirus family includes some of the deadliest viruses known, including Ebola virus and Marburg virus. These viruses cause periodic outbreaks of severe disease that can be spread from person to person, making the filoviruses important public health threats. There remains a need for approved drugs that target all or most members of this virus family. Small molecule inhibitors that target conserved functions hold promise as pan-filovirus therapeutics. To date, compounds that effectively target virus entry, genome replication, gene expression, and virus egress have been described. The most advanced inhibitors are nucleoside analogs that target viral RNA synthesis reactions.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18796257183013
Publisher Site
http://dx.doi.org/10.1016/j.coviro.2019.03.001DOI Listing
April 2019
5 Reads

Publication Analysis

Top Keywords

ebola virus
8
small molecule
8
virus
6
remains approved
4
threats remains
4
members virus
4
virus egress
4
approved drugs
4
drugs target
4
target
4
target members
4
health threats
4
making filoviruses
4
person making
4
person person
4
virus entry
4
advanced inhibitors
4
filoviruses public
4
virus family
4
public health
4

Similar Publications